|
16 Companies |
|
21 Products |
|
21 Products |
|
29 Mechanisms of Action |
|
0 Trials |
|
36 News |
|
- | Phase classification: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Oct 10, 2018
P1, N=28, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1
- | Enrollment change: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - May 25, 2017
P=N/A, N=28, Completed, Sponsor: Mayo Clinic
Phase classification: P=N/A --> P1 N=120 --> 28
- | Trial completion, Trial primary completion date: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Mar 22, 2017
P=N/A, N=120, Completed, Sponsor: Mayo Clinic
N=120 --> 28 Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2013
- | Trial completion, Trial primary completion date: Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1 (clinicaltrials.gov) - May 19, 2016
P=N/A, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Oct 2013 Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016
- ||| Trial completion, Trial initiation date, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 19, 2016
P=N/A, N=70, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> May 2016 Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 19, 2016
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | Initiation date: Mar 2012 --> May 2016 | Trial primary completion date: Jan 2100 --> May 2016 Active, not recruiting --> Completed
- | arsenic trioxide / Generic mfg.
Trial completion, Metastases: Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors (clinicaltrials.gov) - Nov 24, 2015
P2, N=22, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Suspended --> Completed
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial completion, Enrollment change, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - May 26, 2015
P1b, N=78, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed | N=120 --> 78
- ||| Enrollment open, Trial primary completion date: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - May 8, 2015
P=N/A, N=70, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | N=120 --> 78 Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - May 7, 2015
P1, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | Trial primary completion date: May 2012 --> Jan 2100 N=50 --> 30
- imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (clinicaltrials.gov) - Apr 15, 2015
P2, N=100, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 30 Active, not recruiting --> Completed
- || Trial primary completion date: Combination Chemotherapy in Treating Patients With Sarcoma (clinicaltrials.gov) - Apr 14, 2015
P=N/A, N=120, Active, not recruiting, Sponsor: Mayo Clinic
Active, not recruiting --> Completed Trial primary completion date: May 2014 --> Sep 2015
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2014 --> Sep 2015 Trial primary completion date: Nov 2014 --> Apr 2015
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Enrollment change, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P2b, N=133, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Recruiting --> Active, not recruiting N=370 --> 133
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
N=370 --> 133 Trial primary completion date: Aug 2014 --> Nov 2014
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 18, 2014
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2014 --> Nov 2014 N=30 --> 50
- | tanespimycin (BMS-722782) / BMS
Trial completion: Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=70, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 50 Active, not recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Metastases: Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors (clinicaltrials.gov) - Nov 25, 2013
P2, N=0, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Surgery: Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma (clinicaltrials.gov) - Nov 25, 2013
P3, N=400, Completed, Sponsor: Societe Internationale d'Oncologie Pediatrique
Active, not recruiting --> Completed Active, not recruiting --> Completed
- BI2536 / Boehringer Ingelheim
Trial completion, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 3, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- BI2536 / Boehringer Ingelheim
Enrollment change, Metastases: BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors (clinicaltrials.gov) - Sep 19, 2013
P2, N=76, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed N=185 --> 76
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, J&J
Trial termination, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 25, 2013
P2b, N=370, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=185 --> 76 Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III.
- Enrollment change: Glutamine in Preventing Oral Mucositis in Patients Receiving Chemotherapy for Sarcoma (clinicaltrials.gov) - Jul 8, 2013
P=N/A, N=0, Withdrawn, Sponsor: Children's Oncology Group
Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. N=180 --> 0
- | ganitumab (AMG 479) / Takeda, ImmunityBio
Trial completion: QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors (clinicaltrials.gov) - Jun 12, 2013
P2, N=38, Completed, Sponsor: Amgen
N=180 --> 0 Active, not recruiting --> Completed
- arsenic trioxide / Generic mfg.
Enrollment change, Metastases: Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors (clinicaltrials.gov) - Apr 15, 2013
P2, N=22, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=120 --> 22
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas (clinicaltrials.gov) - Mar 19, 2013
P2, N=52, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=120 --> 22 N=102 --> 52
- cixutumumab (IMC A12) / Eli Lilly
Enrollment closed, Metastases: Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 10, 2013
P1, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=102 --> 52 Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment open, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Mar 3, 2013
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting
- exatecan mesylate (DX-8951f) / Daiichi Sankyo
Trial completion: Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor (clinicaltrials.gov) - May 14, 2012
P2, N=0, Completed, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas (clinicaltrials.gov) - Apr 13, 2012
P2, N=60, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Clinical: Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas (clinicaltrials.gov) - Mar 26, 2012
P=N/A, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
- Enrollment closed: Studying Genes in Samples From Younger Patients With Desmoplastic Small Round Cell Tumor Registered on COG-D9902 or COG-ABTR01B1 (clinicaltrials.gov) - Sep 19, 2011
P=N/A, N=20, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting